Binding of cGMP to the GAF-B domain of phosphodiesterase 2A allosterically activates catalytic activity. We report here a series of mutagenesis studies on the GAF-B domain of PDE2A that support a novel mechanism for molecular recognition of cGMP. Alanine mutations of F438, D439, and T488, amino acids that interact with the pyrimidine ring, decrease cGMP affinity slightly but increase cAMP affinity by up to 8 fold. Each interaction is required to provide for cAMP/cGMP specificity. Mutations of any of the residues that interact with the phosphate-ribose moiety or the imidazole ring abolish cGMP binding. Thus, residues that interact with the pyrimidine ring collectively control cAMP/cGMP specificity, while residues that bind the phosphate-ribose moiety and imidazole ring are critical for high affinity binding.
INTRODUCTION
Eleven different phosphodiesterase (PDE) families, each containing multiple genes, have been described and differ in substrate specificity, regulatory properties, inhibitor profiles, and tissue distribution (1) . The cGMP-stimulated PDEs (PDE2s) are one of three families of PDEs (PDE2s, PDE5s, and PDE6s) that are confirmed to contain allosteric cyclic nucleotide binding sites that bind cGMP (2) . Two other cGMP PDE families, PDE10A and PDE11A, have homologous regulatory segments (3, 4) . In PDE2A, cGMP binding to an allosteric site stimulates catalytic activity, which has numerous physiological consequences in vivo. For example, atrial natriuretic peptide (ANP) stimulation of cGMP production and subsequent activation of PDE2A in the adrenal cortex decreases aldosterone secretion, thereby possibly mediating the hormone's effect on fluid volume (5) .
Previous studies have shown that 1 mole of cGMP is bound per PDE2 monomer (6) .
Each PDE2A monomer contains a tandem pair of domains (GAF-A and GAF-B) that are now known to be part of a large family of small molecule binding domains called GAF domains ( Figure 1 ) (7, 8) . GAF domains were first recognized by sequence homology in cGMP-specific PDEs, bacterial adenylyl cyclases, and FhlA, a bacterial transcription modulator; they have now been shown to exist in over 1360 different proteins in organisms ranging from humans to sponges (7, 8) . Cyclic GMP appears only to bind GAF-B in PDE2A (9) and GAF-A in PDE5A (10) . Recently, a mammalian PDE2 GAF domain has been shown capable of activating the adenylyl cyclase cyaB1 of Anabaena, a species of cyanobacterium, demonstrating that the function of these domains have been conserved in species separated by over 2 billion years of evolution (11) .
The GAF domains of cGMP-regulated PDEs and Anabaena adenylyl cyclase cyaB1 are distinguished from most other GAF domains by the presence of a conserved NKX n FX 3 DE by guest on November 17, 2017 http://www.jbc.org/ Downloaded from (NKFDE) motif (12) . The NKFDE motif is conserved in almost all PDE GAF domains and has been proposed to be involved directly in cGMP binding (13) (14) (15) . In the bovine PDE5A holoenzyme, substitution of N276, K277, or D289 with alanine in the NKFDE motif of the GAF-A domain has been reported to increase the apparent K D for cGMP from 1.3 µM to between 12 and 60 µM (13) . In the human PDE5A GAF-A domain expressed alone, however, mutation of the aspartate in the NKFDE motif to alanine (D299A) only weakened binding by 3 fold from 27 nM to 78 nM (16) . The high affinity binding for the human isoform was attributed to the absence of the GAF-B and N-terminal domains of PDE5A in the expression construct (16) .
In the crystal structure of PDE2A GAF-A/B, the NKFDE motif residues of GAF-B are not in contact with cGMP (9) . On the contrary, they are at the other side of a ß sheet making up the floor of the cGMP binding pocket of the GAF-B domain, far from the cGMP binding site ( Figure 2A ) (9) . The crystal structure of PDE2A GAF-A/B also shows continuous electron density between the lysine and aspartate in this motif which may indicate that a salt bridge forms between these residues (9) .
The ability of cAMP-and cGMP-dependent kinases, cyclic nucleotide-gated channels, and cyclic nucleotide phosphodiesterases to discriminate between cAMP and cGMP is an integral part of how these signaling pathways react to cellular stimuli. A single amino acid has been shown to be critical in controlling the specificity of cyclic nucleotide binding to cAMP-and cGMP-dependent kinases, cyclic nucleotide gated channels, and adenylyl and guanylyl cyclases (17) (18) (19) . Many high affinity guanine nucleotide binding proteins utilize the carboxylate group of an aspartate or glutamate residue to bind both the N-1 and N-2 of cGMP (17, (20) (21) (22) (23) . However, there have been relatively few studies probing these details in PDEs. In one study, mutagenesis of D289 within the cGMP binding GAF domain of PDE5A was shown to influence cAMP/cGMP specificity when the pH was lowered from 9.5 to 5.2 (24) . Otherwise, little is known about the molecular determinants of substrate specificity for any GAF domain-containing protein.
The amino acid residues in close contact with the nucleotide have been revealed in the crystal structures of several nucleotide binding proteins in complex with substrates or analogs (25) (26) (27) (28) . However, it also is known that the crystal structure of a complex often does not adequately characterize the relative importance of each close residue for nucleotide binding or nucleotide discrimination. In the present study, we used the recently determined 2.9-Å crystal structure of PDE2A GAF-A/B bound to cGMP (9) as a guide for mutagenesis to determine to what extent various residues lining the GAF-B domain pocket determine cAMP and cGMP binding affinity and specificity.
EXPERIMENTAL PROCEDURES
Materials. [8- 3 H]cGMP and [5, H]cAMP were purchased from NEN (Boston, MA). cAMP (sodium salt), cGMP (sodium salt), epoxy-activated Sepharose 6B, pepstatin A, phenylmethylsulfonyl fluoride (PMSF), dithiothreitol (DTT), and isopropyl-ß-Dthiogalactopyranoside (IPTG) were obtained from Sigma.
Cloning and Site-Directed Mutagenesis. cDNA for mouse PDE2A2 GAF-A (residues 206-386), GAF-B (residues 398-553), GAF-A/B + catalytic domain (GAF-A/B+C) (residues 207-933)
were cloned into a derivative of the pMW172 vector ( Figure 1 ) (29) . GAF-A/B (residues 207-566) had previously been cloned into the same vector (9) . The vector-derived sequence LE(H6) was appended to the C-terminus, and a Met to the N-terminus. The QuikChange site-directed mutagenesis kit (Stratagene) was used to make point mutations in the pMW172 clone according to the protocol from Stratagene. Mutagenic oligonucleotides (Table 4, supplemental materials) were ordered from Integrated DNA Technologies (Coralville, IA). E. coli XL-1 blue cells were used for all DNA manipulations. DNA was purified from small-scale vector preparations using a Qiagen Plasmid Mini kit according to the manufacturer's protocol. DNA segments subjected to mutagenesis and subcloning reactions were sequenced in their entirety to ensure the presence of the desired mutation and proper in-frame subcloning. The same procedures and oligonucleotides were used to make the PDE2A GAF-A/B plus catalytic domain constructs (A/B+C).
Expression of Wild Type and Mutant PDE2 GAF Domains. Wild type and mutant GAF domains
were expressed in C41 (30), a derivative of the E. coli strain BL21(DE3). The mutants were expressed at levels comparable to that of the wild-type GAF domains (5-7 mg/L of culture).
Luria broth with 50 µg/ml ampicillin was used and cells were first grown at 37 ºC until OD 600 =0.5. The cells were then induced with IPTG (30 mg/L), and incubated at 16 ºC for 22
hours. Cells were disrupted in lysis buffer (100 mM NaCl, 20 mM Tris pH 7.5, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM PMSF, and 1 mM ß-mercaptoethanol) by microfluidization (10,000 psi) (Microfluidics, Newton, MA) (31), and then centrifuged at 16,000
x g for 15 minutes. The supernatant was filtered through Whatman filter paper and then chromatographed through an epoxy-Sepharose cGMP affinity column (32) . After elution with 1 mM cGMP (200 mM NaCl, 20 mM Tris pH 7.5, 0.1 mM EDTA, and 1 mM ß-mercaptoethanol) and concentration using a Centriplus centrifugal filter (Amicon), aggregated protein was removed by gel filtration on Superose 12 (Amersham Pharmacia) in 100 mM NaCl, 20 mM Tris pH 7.5, 0.5 mM EDTA, 1 mM ß-mercaptoethanol, and 1 mM DTT.
All the mutated proteins that were purified on the cGMP-affinity column migrated on the gel with essentially the same mobility as that of the wild type GAF domain. Thus, we assume that these single nucleotide changes did not substantially affect transcription, translation, or folding of the protein, and that the cGMP binding affinity changes were not due to global effects on protein folding.
by guest on November 17, 2017 http://www.jbc.org/
Downloaded from
Mutant GAF proteins that did not bind to the cGMP affinity column were purified using Talon metal affinity resin (Clontech) using the protein's C-terminal 6-HIS tag. Cells were disrupted as above, and the supernatant incubated for 1 hour at 4 ºC with Talon resin (5 mL resin/liter culture) pre-washed three times at 700 x g in wash buffer (100 mM NaCl and 20 mM Tris pH 7.5). After incubation, the resin was washed 3 times, transferred to a 20 mL Econo-Pac column (Bio-Rad), and washed again with 10 bed-volumes of wash buffer. The resin was then washed once with 10 mM imidazole and protein eluted with 150 mM imidazole in 100 mM NaCl and 20 mM Tris pH 7.5, followed by gel filtration on Superose-12. These mutations also Other Methods: Total protein concentrations were determined by the method of Bradford, using bovine serum albumin as the standard (Pierce).
RESULTS

F438, D439
, and T488 determine cyclic nucleotide discrimination -We reasoned that one or more of the residues that interact with or are near the positions where the structure of cAMP and cGMP are different should control cyclic nucleotide specificity. Constructs containing mutations of these residues in PDE2 GAF-A/B were expressed in bacteria and purified using a cGMPaffinity column ( Figure 3) . The fact that all could bind to and be eluted from the affinity column strongly suggests that each could fold properly. To analyze the effects on substrate selectivity, full IC 50 curves for both cGMP and cAMP were determined for the wild type and each mutant. Figure 4) . Therefore, the selectivity ratio changes by 16 fold. The increased affinity for cAMP also indicates that these mutations were not generally deleterious to either the overall structure or to the binding pocket of PDE2A GAF-B.
Furthermore, the results indicate that a major effect of each mutation is to remove a negative determinant for cAMP binding. Thus, those residues that determine specificity within the binding site appear mostly to restrict the access of cAMP rather than increase the affinity for cGMP.
D439 was replaced with an uncharged asparagine to determine if the carbonyl of the side chain of D439N could form a similar hydrogen bond to that of D439. We also wanted to test if the amino group of the side chain could hydrogen bond to the deprotonated N-1 of cAMP and increase affinity. D439N has a similar affinity (28±11 nM) for cGMP as wild type (25±2 nM) (Table 1) . This shows that a negatively charged side chain is not necessary for cGMP specificity. A hydrogen bond between the D439 or D439N side chain and cGMP may still be necessary, as D439A has a slightly lower affinity for cGMP (61±3 nM) than wild type. As predicted, D439N does increase the affinity for cAMP (131±27 nM) versus wild type (247±14 nM). However, a partial steric clash also is suggested by the fact that D439A, has an apparent affinity of 46±13 nM, that is higher than wild type (247±14 nM) or D439N (131±27 nM).
Therefore, the presence of D439 allows for high affinity cGMP binding, but either the aspartate or asparagine side chain antagonizes cAMP binding relative to alanine. A mutation to proline of D439 increases the IC 50 for cGMP (152±31 nM) to the same levels as cAMP (158±32 nM), which was slightly lower than for wild-type.
Charged, polar or aromatic substitutions of F438 (F438D, F438E, F438Q, and F438Y) as well as D439H in PDE2A GAF-B (Table 2 ) also gave IC 50 values that showed weaker cGMP affinity but enhanced cAMP affinity. As with PDE2A GAF-A/B, these GAF-B mutants expressed at comparable levels, bound to a cGMP-affinity column, and had an identical mobility on SDS-PAGE as the wild-type protein suggesting that they were correctly folded, full length, and capable of binding cGMP. The fact that non-alanine substitutions of F438 and D439 gave similar affinities as the alanine mutations argues that both the phenylalanine and aspartate residues are unfavorable for cAMP binding, rather than enhancing for the binding of GMP.
Effect of double and triple PDE2A GAF-B mutants on nucleotide specificity -The previous data suggest that all the residues that interact with the pyrimidine ring are required for cyclic nucleotide discrimination and that loss of any one residue is sufficient to lose specificity. To investigate the hypothesis that combinations of changes to the F438, D439, and T488 binding sites might alter cAMP/cGMP specificities in a manner that even reversed selectivity, a number of double and triple mutants were created in PDE2A GAF-B. F438D, F438E, and D439H
substitutions were used in some of the double and triple mutants because their single mutations gave slightly larger cAMP/cGMP ratio shifts than the alanine mutations. All the double and triple mutants had IC 50 values similar to the individual single mutations (Table 2) , and the cAMP and cGMP competition curves become nearly superimposable. Thus, the effect of the double and triple mutants at the binding site appears to mimic the changes in binding caused by any of the single mutations to F438, D439, or T488.
Phosphate-ribose moiety and imidazole ring contacts are critical for cGMP binding -The crystal structure of PDE2A GAF-A/B with cGMP bound shows the residues that define the binding pocket ( Figure 2B ) (9) . The relative importance of those amino acids that make close contact with the cyclic nucleotide in PDE2A GAF-A/B were investigated by mutating each to alanine and the affinity and specificity of the resultant proteins for both cAMP and cGMP were measured ( Table 1) . Most of these mutant proteins could be isolated on a cGMP-affinity column, and therefore were presumably folded correctly. Those that did not bind to the affinity column were investigated after purification on Talon resin and size exclusion chromatography.
Individual alanine substitutions of each residue that interacts with the phosphate-ribose moiety (A459, V484, D485, T492, and E512) or imidazole ring (S424) resulted in a decrease of cyclic nucleotide binding to below detectable levels ( Table 1) .
NKFDE motif is required for cGMP binding -Since the NKFDE motif residues are conserved within many mammalian PDE and Anabaena adenylyl cyclase GAF domains, it has been predicted that this motif is directly involved in binding cyclic nucleotides. However, in the PDE2A crystal structure, the NKFDE motif is found away from the binding pocket (9) . Thus, we sought to determine whether these residues play a role in cGMP binding to PDE2A, as has been suggested in PDE5A (13) . All five NKFDE residues of PDE2A GAF-B were changed to alanine individually and the mutants were tested for cGMP binding. Isolation of these proteins required use of the 6-His tags and purification using Talon resin because none of them bound to the cGMP-affinity resin. When tested by filter binding assay, none of these mutant proteins bound cGMP at detectable levels (Table 1) . To test if the K-D salt bridge stabilized a conformation that allows cGMP to bind in the binding pocket, three mutants were created: NDFDE (K516D), NKFKE (D526K), and NDFKE (K516D/D526K), where the K and D residues were switched for each other. None of these three mutants bound cGMP at detectable levels ( Table 1 ), suggesting that each prevented the proper formation of the cGMP binding pocket in PDE2. These results differ from the effects of a similar mutation in PDE5 where much smaller decreases in cGMP binding affinity were seen (13) .
GAF-A and the catalytic domain alter cGMP binding affinity to GAF-B of PDE2A -PDE2A is
composed of an N-terminal domain, tandem GAF domains (A and B), and a C-terminal catalytic domain (C) ( Figure 1 ). As shown in Table 1 , mouse PDE2A GAF-A/B binds cGMP with an IC 50 of 25±2 nM, or as much as 40 times lower than previously reported for the bovine PDE2A1
holoenzyme (34, 35) . In the holoenzyme, binding of cGMP to the allosteric GAF-B region results in activation of the catalytic domain, as shown by a greater than 10 fold increase in activity (36) (37) (38) (39) . To test the hypothesis that the presence of the catalytic and N-terminal domains would affect cGMP binding to GAF-B, the holoenzyme and a number of GAF domain proteins were expressed and binding affinities measured under exactly the same conditions as for the GAF-B domain alone.
Mouse PDE2A, GAF-A, GAF-B, GAF-A/B, and GAF-A/B+C were expressed in bacteria as described under Methods. The catalytic activity of the baculovirus-expressed bovine PDE2A1
holoenzyme (~60±4 µmol/min/mg at 40 µM cGMP substrate) agreed well with values reported in the literature for pure enzyme isolated from heart or adrenal gland (32) . Purified PDE2A GAF-A does not bind either cAMP or cGMP at detectable levels (Table 1) 
GAF-B (146±10 nM) is almost 2 fold less than GAF-A/B (247±14 nM), 3 fold less than GAF-
A/B+C (400±20 nM) and 6 fold less than the holoenzyme (598±47 nM) ( Figure 5 ). Thus, the presence of GAF-A appears to decrease both cAMP and cGMP affinity, while the N-terminus and catalytic domain appear to have a further effect to diminish cAMP but not cGMP affinity.
GAF-B mutations do not greatly affect global stability or global folding -It was possible that
the effects of some of the mutations described previously were due to effects on the stability or global folding of the expressed proteins. We were particularly worried about the mutations made in the NKFDE region and those in close contact with the ribose moiety as they showed no cGMP binding. Therefore, we developed a GAF-A + GAF-B +catalytic domain bacterial expression vector, GAF-A/B+C). This allowed the effects of mutations on more than one functional domain to be measured. Interestingly, the specific catalytic activity (Vmax) of the bacterially expressed A/B+C wild type construct was very high, in fact as much as 4 times higher than the highest activity reported in the literature for any native holoenzyme (2,6). As shown in Table 3 , the A459S, K516A, or F522A mutations on A/B+C abolished high affinity cGMP binding as they did in the isolated GAF domains alone. However, each of these constructs still had high catalytic activity (25-55% of recombinant wild-type A/B+C and >100% of the value reported for holoenzyme purified by classical procedures from bovine heart). Therefore, it appears that the mutations did not cause a global denaturation of the protein.
DISCUSSION
Roles of F438, D439, and T488 in GAF-B of PDE2A -F438, D439, and T488 appear to control nucleotide specificity in the PDE2A GAF-B binding site. The mutation F438A in PDE2A GAF-A/B changed the wild type IC 50 values from 247±14 nM to 82±3 nM for cAMP and from 25±2 nM to 61±12 nM for cGMP. Therefore, the ability of GAF-B to discriminate between cGMP and cAMP clearly relies at least in part on residue F438. The crystal structure of PDE2A GAF-A/B shows that the side chain of F438 is base stacked with the guanine ring ( Figure 2B ) (9) .
Stacking interactions are common in many nucleotide-binding domains. For example, in the crystal structure of glycogen phosphorylase, aromatic amino acids in the binding sites base stack with the adenine rings of AMP and NADH (27) . It has been postulated from analog studies that there is a difference in polarization potential of the purine ring of cAMP versus cGMP toward polarizable amino acid side. Since the magnitude and direction of the dipole moment of the purine ring in cGMP is significantly different than in cAMP, the guanine base would be expected to have different dipole-induced dipole interactions with the polarizable F438 (40). These differences have been used to explain catalytic specificity preferences for cyclic nucleotide analogs at the PDE2 catalytic site (39, 40) . Actually, since these studies were conducted with PDE2 holoenzyme and we now know that the GAF domains can regulate the activity of the catalytic domain of the enzyme, it may be that the measured catalytic activities were in part due to differences in GAF domain binding of the analogs. Regardless of whether the changes seen with these early studies were due to GAF domain or catalytic domain binding, the changes in In PDE2A GAF-B, D439 also makes a similar hydrogen bond to N-1 with its carboxylate; however, it does not bind to N-2. This allows the other two residues to interact with the guanine ring through a water molecule or base stacking. Thus, F438, D439, and T488 all must be present in order to achieve the selectivity found in the GAF-B binding site.
Furthermore, unlike other cyclic nucleotide binding sites, cGMP is bound in its extended, anticonformation and the phosphate group of cGMP is stabilized in part by the dipole of helix α3 (9). Therefore, PDE2A GAF-B offers an alternative model for high affinity guanine nucleotide binding by demonstrating how multiple residues may act in concert to control nucleotide discrimination.
Mechanism of cyclic nucleotide binding -
The data presented suggest that the residues contacting the phosphate-ribose moiety are absolutely required for high affinity cGMP binding to the GAF-B domain. V484 makes van der Waals contact with the ribose ring, and its replacement with a threonine abolishes cGMP binding. If this side chain rotates 90 degrees, the hydroxyl group from the threonine would be better exposed to solvent, but this is apparently overridden by the fact that the gamma methyl group would then clash with ribose ring oxygen ( Figure 2B ).
Even mutations to serine or threonine of A459, a residue that makes backbone contacts to the phosphate-ribose moiety, abolish cGMP binding. The Cß of A459 is buried within the binding pocket and is in close proximity with E512 ( Figure 2B and 2C) . Thus, the hydrophilic hydroxyl groups on serine and threonine may disturb packing in the region, displace HOH3, or form hydrogen bonds with the OE1 of E512. Any of these factors individually or in concert may explain the apparent loss of cGMP binding seen in this mutant. The side chain of D485 forms a 3.2-Å hydrogen bond contact with HOH1 that binds to the pyrimidine ring and forms a van der Waals contact with HOH2 that binds to the ribose ring (9).
The backbone amide of D485 forms a 3.0-Å hydrogen bond contact also with HOH2 that binds to the ribose ring ( Figure 2C ) (9) . Thus, D485A removes the side chain and van der Waals contacts, which would likely perturb the hydrogen bonds mediated by the two waters and cause the loss of cGMP binding seen in this mutant.
The complete loss of cGMP binding observed for mutations at residues that interact with the phosphate-ribose moiety of cGMP suggests that the majority of the energetic contribution for binding may be attributed to the phosphate-ribose ring binding residues, which stabilize the nucleotide bound form of the enzyme. In studies on the bovine rod cyclic nucleotide-gated ion channel, the closed channel also has been suggested to bind the cyclic nucleotide primarily through its ribose and phosphate (17) . In this channel, the purine ring of the cyclic nucleotide does not appear to be important for initial binding to the channel, but rather its interactions with the side chain of an aspartate in the binding site appear to control the allosteric conformational change leading to channel opening (17) . Thus, a significant portion of the binding energy residing within the bonds formed between the nucleotide ribose and phosphate and the binding pocket residues may be a widespread mechanism by which many high affinity guanine nucleotide binding proteins stabilize cyclic nucleotides within their binding sites. It was surprising that a single alanine mutation within the binding pocket could abolish binding. These mutations may have affected the local folding of the protein, or perhaps disturbed a network of hydrogen bonds making the protein sensitive to the removal of one of them. Such hydrogen bond networks that are sensitive to single changes have been discussed previously (43, 44) . 
NKFDE motif may link GAF-B and the catalytic domain -Initially it was a great surprise to
find that none of the NKFDE residues of GAF-B are in contact with cGMP, since they were conserved in most cGMP-binding PDEs and since mutation of the NKFDE reduced binding in PDE5. Therefore, it was important to determine the effects of mutations to these residues in PDE2. Again, somewhat unexpectedly, mutations to these residues completely abolished cGMP binding. From the crystal structure, it seemed possible that mutations of the NKFDE motif may disrupt interactions between E512 and cGMP, as E512 is near N515, at the beginning of the motif. E512 is a critical residue in the binding pocket (Table 1) . It also seems possible that the substitutions NDFDE (K516D), and NKFKE (D526K) would disrupt the salt bridge within the NKFDE motif and that this bridge is required for cyclic nucleotide binding ( Figure 2A ).
Moreover, the NDFKE (K516D/D526K) result further suggests that the order of the residues, K followed by D, is essential. It remains a possibility that the lack of binding seen in the NKFDE mutants is because this motif is essential for correct folding and nothing else. However, the data with the A/B+C construct would argue against this possibility. Since the catalytic activity of these constructs remained largely intact, the mutations clearly did not introduce a large global change in the protein. The fact that the specific activity is higher than the wild type may suggest that some part of the molecule, presumably the N-terminal region, normally inhibits catalytic activity. However, this hypothesis will take further experimentation to test rigorously. Why the NKFDE motif is so well conserved and absolutely required for binding in PDE2A clearly deserves further investigation but may require crystallization to solve. different from cAMP-induced changes (6) . In earlier studies, the cGMP-bound enzyme was shown to be more susceptible to chymotrypsin inactivation than the cAMP-bound enzyme (6,45).
Differential effects of cAMP and cGMP -
The major chymotrypic cleavage site exposed by cGMP binding is at tyrosine 553 (6) (Table 1) . Again, the complete explanation for these differences will probably require a crystal structure for the holoenzyme in the bound and unbound state.
The apparent cAMP and cGMP binding affinities reported here for all the PDE2A GAF domain proteins, including the holoenzyme, are substantially higher than those previously reported (6, 32, 34, 36, 47) . This is likely because the assays performed in this study used very low protein concentrations (~1 nM). In order for the IC 50 value to approach K i , the level of protein in the assay must be substantially less than the K d of the radioligand. 1 Most if not all of the previously reported cAMP and cGMP binding affinity studies have been performed at much higher protein concentrations or used cell extracts where the exact enzyme concentration was unknown (6, 32, 34, 36, 47) . In retrospect, it can be calculated that nearly all of these earlier studies did not meet the normal Michaelis-Menton assumption that the concentration of the ligand be much higher than the binding protein. Therefore, for high affinity binding sites, this would have resulted in an apparent titration until ligand levels started to exceed protein concentration. Experimentally, in the present studies when the protein concentration was decreased, lower IC 50 values for cGMP for the wild type enzyme were observed. Thus, previously reported cGMP affinities for PDE2A (6, 32, 34, 36, 47) are likely to be artificially low due to this effect. Another formal possibility, however, is that the higher dilutions used in the current studies cause a dilution-induced disaggregation of PDE2 to a form that has a higher intrinsic binding affinity.
Regardless of the reason, the question arises as to the possible physiological consequences of such high affinity sites. In many tissues with high local concentrations of PDE2A, such as brain, adrenal gland, and olfactory cilia, enzyme levels are likely to be quite high, well above "basal" cGMP concentrations (5, 49, 50) . Under these conditions, where the GAF domains would not be fully occupied, the high affinity binding site on PDE2A would be expected to function as a fast, sensitive, on switch for PDE2 when cGMP is increased. The off rate of the switch would then be determined by the off rate of the nucleotide from the GAF domain.
Examples of very rapid cyclic nucleotide changes have been seen in olfactory neurons (51), astrocytes and strial cells (52) , platelets (53, 54) , and the heart (55), all of which are known to contain high levels of PDE2A. Such a fast response to cGMP could clearly be related to the rapid activation of PDE2 caused by cGMP binding to the GAF-B domain. If the GAF domains are as exquisitely sensitive to cyclic nucleotide concentrations in intact tissues as in these in vitro studies and no other factors in the cell are identified that modulate cGMP affinity, we may need to re-evaluate our ideas about regulation of this enzyme in physiological situations.
Finally, these studies raise questions about the mechanisms by which cyclic nucleotide binding to the GAF-B domain is allosterically coupled to changes in activity at the catalytic site. This is especially true since the concentrations of cyclic GMP that allosterically activate the holoenzyme in vitro are much higher than the cGMP affinity constants determined in this study.
A complete analysis of the effects of the mutations described in the present study on the PDE2 holoenzyme as well as mutations at the dimerization interfaces and likely in the catalytic domain will probably be needed to fully address this problem. Ultimately, it likely will require solution of the structure of the holoenzyme in order know where to begin these studies.
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